<DOC>
	<DOCNO>NCT00066625</DOCNO>
	<brief_summary>Phase I trial study effect body combine oxaliplatin bortezomib treat patient metastatic unresectable cancer . Drugs use chemotherapy oxaliplatin use different way stop cancer cell divide stop grow die . Bortezomib may stop growth cancer cell block enzymes necessary tumor cell growth . Combining oxaliplatin bortezomib may kill cancer cell</brief_summary>
	<brief_title>Oxaliplatin Bortezomib Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose oxaliplatin bortezomib patient advanced malignancy . II . Determine dose-limiting toxicity regimen patient . III . Determine toxicity profile regimen patient . IV . Determine antitumor activity regimen patient . V. Determine pattern neurotoxicity reversibility patient respond prolonged administration treatment regimen . VI . Determine whether pharmacokinetics pharmacodynamics oxaliplatin bortezomib alter administration agent patient . OUTLINE : This dose-escalation study . Patients receive oxaliplatin IV 2 hour day 1 15 bortezomib IV 3-5 second day 1 , 4 , 15 , 18 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oxaliplatin bortezomib maximum tolerate dos ( MTDs ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow least 3 month . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 4-15 month .</detailed_description>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm malignancy standard curative palliative measure exist longer effective Metastatic unresectable disease No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 More 6 month Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST ALT great 5 time upper limit normal Creatinine great 1.5 mg/dL No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biological composition platinum study agents No preexist peripheral neuropathy No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness Prior thalidomide allow provided patient clinical neuropathy Prior platinum antitubulin agent allow provided patient clinical neuropathy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover More 3 week since prior radiotherapy recover No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>